Catalog No.: PC-20195Not For Human Use, Lab Use Only.
Lumiracoxib (COX-189) is a highly selective COX-2 inhibitor with IC50 of 0.14 uM in COX-2-expressing dermal fibroblasts, inhibits purified COX-2 with Ki of 0.06 uM, 50-fold selectivity over COX-1 (Ki=3 uM).
Lumiracoxib (COX-189) is a highly selective COX-2 inhibitor with IC50 of 0.14 uM in COX-2-expressing dermal fibroblasts, inhibits purified COX-2 with Ki of 0.06 uM, 50-fold selectivity over COX-1 (Ki=3 uM).
Lumiracoxib shows no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).
Lumiracoxib shows IC50 of 0.13 uM a human whole blood assay, 515 fold over COX-1.
Ex vivo, lumiracoxib inhibited COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch with an ID(50) value of 0.24 mg kg(-1).
Lumiracoxib showed dose-dependent effect in rat models of hyperalgesia, oedema, pyresis and arthritis.
